Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.

Background: Studies of Her-2/neu protein expression in interval and screen-detected breast cancers have been conflicting. Therefore we assessed the Her-2/neu amplification status in these groups by using in situ hybridization.

Patients And Methods: The Her-2/neu oncogene amplification and protein over-expression were compared in 79 screen-detected and 39 interval breast carcinomas, using a novel and well-documented chromogenic in situ hybridization (CISH) method and immuhistochemistry.